Lenograstim

Therapeutic Group

Immunostimulants

Indication Dosage

Lenograstim is a medication indicated for the treatment of neutropenia, a condition characterized by a low count of neutrophils (a type of white blood cell) in the body. Neutropenia can occur as a side effect of chemotherapy, which can weaken the immune system, making the body more susceptible to infections. Lenograstim helps stimulate the production of neutrophils, thereby reducing the risk of infections in individuals undergoing cancer treatment or bone marrow transplantation.

Reduction In The Duration Of Neutropenia Following Bone-marrow Transplantation Or Peripheral Stem Cells Transplantation For Non-myeloid Malignancy: 

By Sc Inj Or Iv Infusion: 

  • Adult: 150 Mcg/m2 Daily Until Neutrophil Count Stable In an Acceptable Range (max. 28 Days), To Be Started The Day After Transplantation. 

Reduction In The Duration Of Neutropenia Following Treatment With Cytotoxic Chemotherapy Associated With A Febrile Neutropenia: 

By Sc Inj: 

  • Adult: 150 Mcg/m2 Daily Until Neutrophil Countstable In Acceptable Range (max. 28 Days), To Be Started On The Day After Completion Of Chemotherapy 

Mobilization Of Peripheral Blood Progenitor Cells For Harvesting And Subsequent Infusion: 

By Sc Inj: 

  • Adult: 10 Mcg/kg Daily For 4-6 Days 

Mobilisation Of Peripheral Blood Progenitor Cells, Used Following Adjunctive Myelosuppressive Chemotherapy: 

By Sc Inj: 

  • Adult: 150 Mcg/m2 Daily Until Neutrophil Count Stable In Acceptable Range, To Be Started 1-5 Days After Completion Of Chemotherapy,(for Treatment Of Leucopheresis, Consult Product Literature)

Content

  • Inj 263 Mcg: Lenograstim 263 Mcg (33.6 Million Units); Powder In Vials And Water For Injection In Amp.

Pregnancy

Risk Cannot Be Ruled Out.

Stability

  • Recombinant G-csf (recombinant Human Granulocyte-colony Stimulating Factor)

Contra Indications

  • Severe Congenital Neutropenia (kostmann's Syndrome) With Abnormal Cytogenetics.

Precautions

  • Severe Congenital Neutropenia (kostmann's Syndrome) With Abnormal Cytogenetics.

Lactation

  • Caution Advised or Effect Undetermined.

Side Effects

  • Mucositis
  • Splenic Rupture
  • Toxic Epidermal Necrolysis
  • Musculoskeletal Pain
  • Transient Hypoten-sion
  • Disturbances In Liver Enzymes And Serum Uric Acid; Thrombocytopenia; Urinary Abnormalities Including Dysuria; Allergic Reactions (more Common After Intravenous Infusion)
  • Proteinuria
  • Haematuria
  • And Transient Decrease In Blood Glucose; On Long-term Use Cutaneous Vasculitis
  • Splenic Enlargement
  • Hepatomegaly
  • Headache
  • Diarrhoea
  • Anaemia
  • Epistaxis
  • Alopecia
  • Osteoporosis
  • And Rash.

Available Brands